CorNeat Vision is a clinical-stage, biomimetic implants and technology company. Our patented, nondegradable, synthetic platform material – The CorNeat EverMatrix™ – is set to displace harvested and processed human and animal tissues, and degradable Extra Cellular Matrices (ECMs), the protein skeleton of the tissue, used in a variety of surgical procedures across diversified fields of medicine.
The CorNeat EverMatrix™ addresses the main issue with implants and implantables – the foreign body response they trigger leading either to their degradation and absorbance, or encapsulation. The CorNeat EverMatrix™ seamlessly and permanently embeds with live tissue without triggering an inflammatory response. Its durability and flexibility, coupled with its bio-integration capabilities, mark a new era of implants that can:
- Bio-mechanically integrate with surrounding tissue
- Permanently reinforce soft tissue and accelerate its healing
- Act as a membrane for guided soft tissue and bone regeneration
- Conceal irritating implants
- Enable sensors to continuously remain in contact with surrounding tissue
The features and benefits of the CorNeat EverMatrix™ were proven histologically and clinically in over a dozen in-vitro and in-vivo studies, including in humans. Findings demonstrate full fibroblast colonization and abundant collagen deposition with no encapsulation, rendering the CorNeat EverMatrix™ an integral part of the surrounding tissue.
Our initial set of biomimetic implants address unmet needs in the fields of ophthalmology and periodontology. They demonstrate the business potential and social impact of the CorNeat EverMatrix™ and its promise to offer new and disruptive implants significantly superior to predicates.
We have four implants under development. Our flagship product is a self-integrating artificial cornea, the CorNeat KPro, enabling corneally blind patients to regain sight with no reliance on donor tissue. The CorNeat KPro is in the clinical stage and expected to enter the market in 2024. Additional products include: 1) the CorNeat EverPatch, a synthetic tissue substitute for ophthalmic surgeries, also undergoing clinical trials and expected to enter the market early next year; 2) the CorNeat gPatch, a permanent synthetic gingival reinforcement patch that displaces the use of grafts in gum recession surgeries; and 3) the CorNeat eShunt, a self-regulating and long-lasting glaucoma drainage device.